Adeno-associated viral vectors (AAV vectors) are essential tools for delivering gene therapy to patients and are usually manufactured using plasmid-based approaches. However, there are challenges with ...

The publication introduces a genetic identification system that enables plasmids to carry embedded documentation, improving traceability, verification, and secure exchange in biotech research and ...

ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio ...

DUBLIN, Nov. 30, 2020 /PRNewswire/ -- The "CRISPR Technology Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Scientists use plasmids as the leading gene delivery technology for a variety of research and clinical applications related to gene therapy. Traditional approaches to plasmid creation often result in ...

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and ...

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Phase 1 clinical trial results of IMNN-101 ...

DNA plasmid technology has many applications. Inovio’s Covid-19 vaccine may still have a global market. Inovio potential HPV related therapies look headed for success. Glioblastoma therapy success is ...

Inovio reported positive Phase 3 VGX-3100 data. In addition to treating cervical dysplasia, label expansion is likely. DNA plasmid technology is poised to create a broad array of commercial therapies.

As it continues to push its DNA-based interleukin-12 (IL-12) therapy through phase 2 trials and hopes to take on the mRNA vaccine juggernauts, Celsion Corporation has decided now is the time for a ...